Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health
Healthcare Communications | Pharmaceutical Executive | Medical Executive | Tech PR | Scientific Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact Laura on +441494 818 026 or laura@zenopa.com for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Laura Marsh
Account Manager
laura@zenopa.com
+441494 818 026

Testimonials
It has been a great experience working with a company that really cares. Zenopa have been so brilliant all the way, the support they gave me has been first class.
Mechell, 2012

Roche appoints new pharma and diagnostics heads

29 August 2012 11:12 in Pharmaceutical Company Restructures


Roche has announced a series of changes to its corporate executive committee, following the departure from the group of Pascal Soriot.

Daniel O'Day, who has acted as chief operating officer (COO) of Roche Diagnostics since January 2010, will succeed Mr Soriot in the role of COO of Roche Pharma.

Severin Schwan, chief executive officer of Roche, said: "I am very pleased that with Daniel O'Day, we are appointing a new head of Roche Pharma with a very impressive track record in both the diagnostics and pharmaceuticals division."

Meanwhile, Mr O'Day's former post will be filled by Roland Diggelmann, the current head of Asia-Pacific operations at Roche Diagnostics, who will also become part of the executive committee for the first time.

Mr Schwan expressed confidence that Mr Diggelmann will also succeed in his new role, thanks to his experience in commercial and marketing activities on a broad international basis.

Last month, Roche announced a group sales total of 22.4 billion Swiss francs (17.78 billion pounds) for the first half of 2012, up by three percent year over year.ADNFCR-8000103-ID-801437759-ADNFCR

Other news stories from 29/08/2012

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Axonn News Agency



                    
© Copyright 2014 Zenopa Ltd